PET特异性分子探针在肝纤维化早期诊断中的应用

杨梦忆; 许向欣; 辛军

doi:10.3969/j.issn.1001-5256.2016.12.009

PET特异性分子探针在肝纤维化早期诊断中的应用

DOI: 10.3969/j.issn.1001-5256.2016.12.009

中国医科大学附属盛京医院放射科

基金项目:

国家自然科学基金面上项目(81371605);国家自然科学基金面上项目(81471718)；

详细信息

中图分类号: R575.2;R816.5
计量
- 文章访问数: 2182
- HTML全文浏览量: 13
- PDF下载量: 439
- 被引次数: 0
出版历程
- 出版日期: 2016-12-20

Research advances in the application of specific molecular probes for positron emission tomography in diagnosis of early-stage liver fibrosis

Research funding:

摘要

摘要: 肝纤维化是许多慢性肝病的标志性过程,临床上以肝穿刺活组织检查作为肝纤维化的诊断金标准,目前缺乏无创诊断早期肝纤维化的有效手段。肝纤维化进程伴随着复杂的分子水平的物质变化,各种物质变化与肝纤维化进展程度有一定相关性。PET作为能够提供组织功能与代谢等分子水平信息的影像学检查,有能力监测这些定量化信息。简单介绍了应用于早期肝纤维化诊断的PET特异性分子探针的原理,总结了目前PET特异性分子探针对早期肝纤维化诊断、分期的应用价值,以及寻找更多、更合适的PET特异性分子探针应用于早期肝纤维化。
- 肝硬化 /
- 正电子发射断层显像术 /
- 分子探针 /
- 诊断
Abstract: Liver fibrosis is a symbolic process of many chronic liver diseases,and liver biopsy is the gold standard for the diagnosis of liver fibrosis in clinical practice. At present,there is a lack of effective methods for the noninvasive diagnosis of early- stage liver fibrosis. The process of liver fibrosis is accompanied by complicated changes at the molecular level,which are associated with the progression of liver fibrosis. As an imaging examination which can provide the information at the molecular level such as tissue function and metabolism,positron emission tomography( PET) has the ability to monitor such quantitative information. This article mainly introduces the principles of specific molecular probes for PET used in the diagnosis of early- stage liver fibrosis,summarizes the value of these specific molecular probes in the diagnosis and staging of early- stage liver fibrosis,and points out that it is necessary to find more specific molecular probes for the diagnosis of early- stage liver fibrosis.
- liver fibrosis /
- positron-emission tomography /
- molecular probes /
- diagnosis

HTML全文

参考文献(27)

[1]XU J,LIU X,KOYAMA Y,et al.The types of hepatic myofibroblasts contributing to liver fibrosis of different etiologies[J].Front pharmacol,2014,5:167.

[2]XIN J,ZHANG X,CAO L,et al.The application of[18F]FDGRGD peptide in diagnosis of liver fibrosis[J].Prog Anat Sci,2015,21(3):245-248.(in Chinese)辛军,张新,曹礼,等.[18F]FDG-RGD多肽在肝纤维化诊断中的应用价值[J].解剖科学进展,2015,21(3):245-248.

[3]ZHANG X,XIN J,SHI Y,et al.Assessing activation of hepatic stellate cells by99mTc-3PRGD2 scintigraphy targeting integrinαvβ3:a feasibility study[J].Nucl Med Biol,2015,42(3):250-255.

[4]DU M,HAN TT,ZHANG X,et al.Evaluation of[11C]N-methyl acetazolamide PET/CT in early diagnosis of liver fibrosis4[J].J Chin Clin Med Imaging,2015,5(3):183-247.(in Chinese)杜名,韩婷婷,张新,等.[11C]N-甲基乙酰唑胺PET/CT评价肝脏纤维化早期诊断的价值[J].中国临床医学影像杂志,2015,5(3):183-247.

[5]HAN TT,DU M,ZHANG X,et al.Quantitative assessment of early liver fibrosis in rats using 13N-NH3·H2O PET/CT[J].Nucl Med Commun,2016,37(1):92-98.

[6]FRIEDMAN SL.Evolving challenges in hepaticfibrosis[J].Nat Rev Gastroenterol Hepatol,2010,7(8):425-436.

[7]WATSKY MA,WEBER KT,SUN Y,et al.New insights into the mechanism of fibroblast to myofibroblast transformation and associated pathologies[J].Int Rev Cell Mol Biol,2010,282:165-192.

[8]GUO QL,WANG XZ.Role of liver sinusoidal endothelial cells in the formation of hepatic fibrosis[J].Chin Hepatol,2013,18(4):269-273.(in Chinese)郭杞兰,王小众.肝窦内皮细胞在肝纤维化形成中的作用[J].肝脏,2013,18(4):269-273.

[9]TANIGUCHI H,YAMAGUCHI A,KUNISHIMA S,et al.Using the spleen for time-delay correction of the input function in measuring hepatic blood flow with oxygen-15 water by dynamic PET[J].Ann Nucl Med,1999,13(4):215-221.

[10]ZHOU X,MURPHY FR,GEHDU N,et al.Engagement ofαvβ3 integrin regulates proliferation and apoptosis of hepatic stellate cells[J].J Bios Chem,2004,279(23):23996-24006.

[11]MA JX,YE DZ.Advances in tumor treatment with labeled somatostatin analogues[J].Foreign Med Sci:Radiol Nuclear Med,2005,29(2):79-84.(in Chinese)马寄晓,叶大铸.奥曲肽及其类似物用于肿瘤治疗的进展[J].国外医学:放射医学核医学分册,2005,29(2):79-84.

[12]RIEMANN D,HANSEN GH,NIELS-CHRISTIANSEN L,et al.Caveolae/lipid rafts in fibroblast-like synoviocytes:ectopeptidase-rich membrane microdomains[J].Biochem J,2001,354(Pt1):47-55.

[13]PATSENKER E,STICKEL F.Role of integrins in fibrosing liver diseases[J].Am J Physiol Gastrointest Liver Physiol,2011,301(3):g425-g434.

[14]LI F,SONG Z,LI Q,et al.Molecular imaging of hepatic stellate cell activity by visualization of hepatic integrinαvβ3 expression with SPECT in rat[J].Hepatology,2011,54(3):1020-1030.

[15]AGRE P,SASAKI S,CHRISPEETS MJ.Aquaporins:a family of water channel proteins[J].Am J Physiol,1993,265(2):f461.

[16]CARRERAS FI,LEHMANN GL,FERRI D,et al.Defective hepatic aquaporim-8 expression and reduced canalicular membrane water permeability in estrogen-induced cholestasis[J].Am J Physiol Gastrointest Liver Physiol,2007,292(3):1554-1564.

[17]YOKOMORI H,ODA M,YOSHIMURA K,et al.Aquaporin-1associated with hepatic arterial capillary proliferation on hepatic sinusoid in human cirrhotic liver[J].Liver Int,2011,31(10):1554-1564.

[18]IGUCHI H,ODA M,YAMAZAKI H,et al.Aquaporin-1 is associated with arterial capillary proliferation and hepatic sinusoidal transformation contributing to potal hypertension in primary biliary cirrhosis[J].Med Mol Morphol,2014,47(2):90-99.

[19]ROBERT H,MEHER V,UDAY S,et al.Aquaporin-1 facilitates angiogenic invasion in the pathological neovasculature that accompanies cirrhosis[J].Hepatology,2010,52(1):238-248.

[20]WANG F,FENG XC,LI YM,et al.Aqu aporins as potential drug targets[J].Acta Pharmacol Sin,2006,27(4):395-401.

[21]HATORI A,YUI J,XIE J,et al.Utility of translocator protein(18k Da)as a molecular imaging biomarker to monitor the progression of liver fibrosis[J].Sci Rep,2015,5:17327.

[22]KAO HW,CHEN CL,CHANG WY,et al.(18)F-FBHGal for asialoglycoprotein receptor imaging in a hepatic fibrosis mouse model[J].Bioorg Med Chem,2013,21(4):912-921.

[23]SCHUPPAN D,KIM YO.Evolving therapies for liver fibrosis[J].J Clin Invest,2013,123(5):1887-1901.

[24]WELLS RG.The portal fibroblast:notjust a poorman’s stellate cell[J].Gastroenterology,2014,147(1):41-47.

[25]DRANOFF JA,WELLS RG.Portal fibroblasts:underappreciated mediators of biliary fibrosis[J].Hepatology,2010,51(4):1438-1444.

[26]ARAP W,PASQUALINI R,RUOSLAHTI E.Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model[J].Science,1998,279(5349):377-380.

[27]COLOMBO G,CURMIS F,de MORI GMS,et al.Structure-activity relationships of linear and cyclic peptides containing the NGR tumor homing motif[J].J Biol Chem,2002,277(49):47891-47897.

施引文献

资源附件(0)

访问统计